High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report.

Am J Case Rep. 2016 Oct 24;17:774-781.

Mikirova N, Hunnunghake R, Scimeca RC, Chinshaw C, Ali F, Brannon
C, Riordan N.

Abstract

Background:

In neurofibromatosis type 1 (NF1) disease, the loss of the tumor suppressor function of the neurofibromin gene leads to proliferation of neural tumors. In children, the most frequently identified tumor is the optic pathway glioma.

Case Report:

We describe the case of a 5-year-old child who was diagnosed with NF1 and optic pathway tumor onset at the age of 14 months. Because of the tumor progression, chemotherapy with carboplatin and vincristine was prescribed at this early age and continued for one year. As the progression of disease continued after chemotherapy, the child, at the age of 2.8 years, was started on high-dose intravenous vitamin C (IVC) treatment (7–15 grams per week) for 30 months. After 30 months, the results of IVC treatments demonstrated reduction and stabilization of the tumors in the optic chiasm, hypothalamus, and left optic nerve according to radiographic imaging. The right-sided optic nerve mass seen before IVC treatment disappeared by the end of the treatment.

Conclusions:

This case highlights the positive effects of treating NF1 glioma with IVC. Additional studies are necessary to evaluate the role of high-dose IVC in glioma treatment.

link to full text

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Alternative Cancer, Clinical Use, Vitamin C

Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis.

Alternative Cancer, Vitamin C

Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo.

Adipose (Fat), Alternative Cancer, Vitamin C

Anti-angiogenic effect of high doses of ascorbic acid.

Alternative Cancer, Clinical Use, Vitamin C

Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate.

Alternative Cancer, Clinical Use, Vitamin C

Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer.

Alternative Cancer, Clinical Use, Vitamin C

A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.

Alternative Cancer, Clinical Use, Vitamin C

Orthomolecular oncology review: ascorbic acid and cancer 25 years later.

Alternative Cancer, Clinical Use, Vitamin C

Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.

Alternative Cancer, Clinical Use, Vitamin C

L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.

Alternative Cancer, Clinical Use, Vitamin C

Intravenous ascorbic acid: protocol for its application and use.

Alternative Cancer, Clinical Use, Vitamin C

Orthomolecular oncology: a mechanistic view of intravenous ascorbate’s chemotherapeutic activity.

Alternative Cancer, Vitamin C

Inhibition of human breast carcinoma cell proliferation by ascorbate and copper.

Alternative Cancer, Clinical Use, Vitamin C

Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours.

Alternative Cancer, Clinical Use, Vitamin C

Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent.

Alternative Cancer, Clinical Use, Vitamin C